Coya Therapeutics Faces Setback as COYA 302 Delivers Mixed Results in Mid-Stage Study for Frontotemporal Dementia

Investment and Development:
The Alzheimer’s Drug Discovery Foundation (ADDF) invested $5 million in Coya Therapeutics to support the development of COYA 302 for treating Frontotemporal Dementia (FTD).

Clinical Trial Results:
COYA 302, a combination therapeutic approach targeting multiple inflammatory pathways, showed mixed results in a mid-stage study for FTD. The study aimed to suppress neuroinflammation, a promising pathway for chronic neurological diseases like FTD.

Expansion into Alzheimer’s Disease:
Coya Therapeutics expanded COYA 302’s indications to include Alzheimer’s disease (AD), recognizing the shared inflammatory disease pathways between AD, FTD, and other neurodegenerative diseases like ALS and Parkinson’s disease.

Comparison with Other Treatments:
Unlike Lilly’s donanemab, which significantly slowed cognitive and functional decline in early Alzheimer’s disease, COYA 302’s mixed results in FTD highlight the challenges in treating neurodegenerative diseases with complex pathologies.

Future Plans:
Coya Therapeutics plans to continue developing COYA 302, leveraging its proprietary low-dose interleukin-2 (LD IL-2) and CTLA4-Ig combination to target multiple pathways in neurodegenerative diseases.

Financial Support:
The company has a two-year cash runway, supported by partnerships and upfront payments, to further develop COYA 302 and explore its potential across various neurodegenerative indications.